Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0537-1482 · 2 trials · 2 indications
Measured as number of events.
Number of events.
Number of events.
Number of events.
| Arm | Type | Description |
|---|---|---|
| Cohort 1A | EXPERIMENTAL | Participants will be administered once weekly dose level 1 of NNC0537-1482 subcutaneously. |
| Cohort 2A | EXPERIMENTAL | Participants will be administered once weekly dose level 2 of NNC0537-1482 subcutaneously. |
| Cohort 3A | EXPERIMENTAL | Participants will be administered once weekly dose level 3 of NNC0537-1482 subcutaneously. |
| Cohort 4A | EXPERIMENTAL | Participants will be administered once weekly dose level 4 of NNC0537-1482 subcutaneously. |
| Cohort 5A | EXPERIMENTAL | Participants will be administered once weekly dose level 5 of NNC0537-1482 subcutaneously. |
| Cohort B | EXPERIMENTAL | Participants will be administered a selected safe and tolerable dose level of NNC0537-1482 subcutaneously. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered Placebo matched to NNC0537-1482 subcutaneously. |
| NNC0537-1482 Dose level 1 | EXPERIMENTAL | Participants will be administered a single dose of dose level 1 of NNC0537-1482 subcutaneously. |
| NNC0537-1482 Dose level 2 | EXPERIMENTAL | Participants will be administered a single dose of dose level 2 of NNC0537-1482 subcutaneously. |
| NNC0537-1482 Dose level 3 | EXPERIMENTAL | Participants will be administered a single dose of dose level 3 of NNC0537-1482 subcutaneously. |
| NNC0537-1482 Dose level 4 | EXPERIMENTAL | Participants will be administered a single dose of dose level 4 of NNC0537-1482 subcutaneously. |
| NNC0537-1482 Dose level 5 | EXPERIMENTAL | Participants will be administered a single dose of dose level 5 of NNC0537-1482 subcutaneously. |
| NNC0537-1482 Dose level 6 | EXPERIMENTAL | Participants will be administered a single dose of dose level 6 of NNC0537-1482 subcutaneously. |
| Name | Type | Description |
|---|---|---|
| NNC0537-1482 | DRUG | NNC0537-1482 will be administered subcutaneously. |
| Placebo | DRUG | Placebo will be administered subcutaneously. |
Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Male or females of non-childbearing potential. * Age 40-75 years...
NNC0537-1482 is an investigational small molecule being developed by Novo Nordisk A/S for the treatment of heart failure. It is currently in Phase 1 clinical development, with studies evaluating its effects in healthy volunteers and in participants with heart failure.
NNC0537-1482 is being developed by Novo Nordisk A/S, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVO. The drug is currently in Phase 1 clinical trials.
NNC0537-1482 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing to evaluate its safety and effects in healthy volunteers and in participants with heart failure.
NNC0537-1482 is being studied in two Phase 1 trials. NCT06625307, a completed study in healthy volunteers in the Netherlands, and NCT07218627, a recruiting study in participants with heart failure in the United Kingdom. Both trials are randomized, double-blind, and placebo-controlled.
NNC0537-1482 is administered by injection under the skin. This route of administration is being evaluated in clinical trials, including a completed study in healthy volunteers and an ongoing study in participants with heart failure.